O-1A Guide
O-1A for Infectious Disease Modelers: Publications, NIH and CDC Grants, and Field Recognition Evidence in 2026
Infectious disease modelers occupy a research field whose public health relevance has intensified substantially. Petitions under the O-1A extraordinary ability classification draw on epidemiology and computational biology publications, NIH MIDAS and CDC cooperative agreement grants, and expert recognition from academic and public health agency communities.
Infectious disease modeling and the O-1A classification
Infectious disease modeling is a quantitative research field at the intersection of epidemiology, computational science, mathematical biology, and public health policy. Researchers construct mathematical and statistical models of pathogen transmission dynamics, population immunity, intervention scenarios, and outbreak trajectories — providing the analytical infrastructure that public health agencies and policymakers use to evaluate containment strategies, vaccination programs, and resource allocation decisions. High-profile applications to pandemic influenza planning, SARS-CoV-2 spread projection, Ebola outbreak management, and endemic disease burden estimation have elevated the field's public visibility while maintaining its technical rigor. The O-1A extraordinary ability classification applies to researchers whose professional record demonstrates a level of recognized achievement substantially above what is ordinarily encountered among working infectious disease modelers.
The O-1A criteria most productive for infectious disease modelers are scholarly articles in recognized journals, original contributions of major significance, grants from NIH and CDC, and judging and peer review service. Senior researchers at established institutions publish in journals including the Lancet Infectious Diseases, PLOS Medicine, Nature Communications, PLOS Computational Biology, Epidemics, Journal of Theoretical Biology, and BMC Infectious Diseases. High-impact COVID-19 modeling papers published in Science, Nature, Nature Medicine, and the New England Journal of Medicine represent a generation of publications that have complicated the field's citation baseline, requiring careful contextualization of pre-pandemic publication records when presenting an overall career arc to adjudicators.
A structural challenge for infectious disease modelers in O-1A petitions is that the field is inherently interdisciplinary — some researchers come from mathematics, some from epidemiology, some from computer science, and some from biology — which can make field definition and peer comparison difficult. The petition should clearly identify the professional community the petitioner primarily operates within, whether that is the Infectious Diseases Society of America's epidemiology network, the Society for Mathematical Biology, the modeling technical advisory groups convened by CDC, or the MIDAS (Models of Infectious Disease Agent Study) network funded through NIH. Identifying the primary professional community allows the petition to establish peer comparison and expert declarant credibility within a defined field.
Scholarly articles and modeling publications
The scholarly articles criterion requires publications in recognized peer-reviewed journals within the petitioner's field. For infectious disease modelers, established outlets include Lancet Infectious Diseases, PLOS Medicine, PLOS Computational Biology, Epidemics, Journal of Infectious Diseases, Emerging Infectious Diseases published by CDC, BMC Infectious Diseases, and Journal of Mathematical Biology. Publications in Science, Nature, PNAS, Nature Medicine, Cell Host and Microbe, and the New England Journal of Medicine represent high-impact general science and clinical outlet placements that carry strong evidentiary weight because they demonstrate evaluation by generalist expert reviewers at outlets with highly competitive acceptance rates, not only by specialist infectious disease modeling peers.
Citation analysis is the most objective secondary measure of publication impact. A researcher whose modeling papers have been cited by CDC technical reports, WHO guidance documents, or national public health agency planning materials occupies a particularly strong evidentiary position, because those citations demonstrate that the research has been adopted by institutional actors whose function is specifically to translate research into public health practice. Expert declarations identifying the specific CDC or WHO documents that cite the petitioner's work, explaining what role those citations played in the institutional decision-making process, and characterizing the significance of having modeling research incorporated into official guidance provide the analytical bridge between citation metrics and the major significance requirement.
Preprint records on medRxiv and bioRxiv should be distinguished clearly from peer-reviewed publications in the petition. During the COVID-19 pandemic, many highly cited analyses were preprinted before formal peer review, and some accumulated citation records substantially exceeding their subsequent peer-reviewed counterparts. Where the petitioner has preprints with significant citation records and downstream policy impact, those records can be presented as supplementary evidence of public engagement with the petitioner's work — but they should not be characterized as peer-reviewed publications in the scholarly articles criterion analysis, which requires formal publication in recognized outlets.
Original contributions through analytical frameworks
The original contributions criterion under 8 C.F.R. § 214.2(o)(3)(iii)(D) for infectious disease modelers most commonly attaches to the development of novel transmission models, novel statistical methodologies for outbreak parameter estimation, computational frameworks for large-scale outbreak simulation, or analytical approaches for evaluating intervention effectiveness that have been adopted by other research groups or implemented in public health practice. A researcher who developed an SEIR model variant incorporating age-structured contact matrices that other modeling groups subsequently used in their own analyses, or who published a likelihood-based method for real-time reproduction number estimation implemented in CDC's and ECDC's standard epidemic monitoring toolkits, has made a contribution whose major significance can be traced through downstream adoption.
Software tools and modeling frameworks distributed as open-source packages constitute a particularly documentable form of original contribution. A researcher who developed and maintains a widely used R or Python package for infectious disease compartmental modeling — one cited in peer-reviewed publications by other groups and implemented in academic and public health modeling analyses — has produced a contribution whose use can be quantified through package download statistics, GitHub star counts, and citations in the literature. These metrics should be presented alongside expert declaration explaining their significance within the modeling community's norms, since raw download counts without context are not self-explanatory to adjudicators.
Contributions to public health agency technical groups — serving as a modeling expert on a CDC technical advisory group, contributing an analysis to a PAHO or WHO outbreak response team, or developing scenario projections used in a state health department's pandemic preparedness planning — constitute original contributions in the operational sense even when not published in peer-reviewed journals. These should be documented through letters from agency technical staff confirming the petitioner's role, briefing materials or technical reports identifying the petitioner as a contributing analyst, and where possible a declaration from a public health official explaining what the petitioner's specific analytical contribution enabled the agency to do that it could not have accomplished with generic modeling approaches.
NIH and CDC grants as recognition evidence
NIH grants supporting infectious disease modeling research are administered primarily through the National Institute of Allergy and Infectious Diseases, with contributions from the National Institute of General Medical Sciences — which has funded modeling research through the MIDAS program — the National Library of Medicine for computational and informatics approaches, Fogarty International Center for global infectious disease work, and the National Institute of Biomedical Imaging and Bioengineering. R01 grants in this area typically fund transmission modeling, intervention evaluation, and pathogen evolution research with peer review through study sections including Infectious Disease Epidemiology, Statistics, and Biostatistical Methods and Research Design, depending on the application's primary analytical focus.
CDC cooperative agreements represent a second major funding stream for infectious disease modeling researchers, particularly those working on domestically relevant outbreak and endemic disease questions. CDC's Emerging Infections Program, Predict program, and CSTE cooperative agreement mechanisms support modeling work at state and academic public health institutions. The Center for Forecasting and Outbreak Analytics has established relationships with modeling groups through funded partnerships. A grant or cooperative agreement funded by CDC's direct research programs reflects programmatic selection by the agency responsible for U.S. infectious disease surveillance and response — a form of recognition distinct from NIH's scientific merit review and carrying its own significance as applied science validation.
Foundation grants from private sources — the Bill and Melinda Gates Foundation's global health modeling portfolio, the Wellcome Trust's infectious disease epidemiology funding, the Simons Foundation's modeling programs, or DARPA's biological threat research investments — expand the recognition record beyond U.S. government funding to include international and private sector scientific validation. Gates Foundation grants in global infectious disease modeling, in particular, are competitively reviewed and tend to fund work with significant policy implications for disease control. A researcher with active Gates Foundation support for transmission modeling is recognized by an evaluator assessing research with public health impact at a global scale, not merely by domestic academic peer review.
Judging and critical role documentation
Judging and peer review service for infectious disease modelers encompasses review assignments for journals including Lancet Infectious Diseases, Epidemics, and PLOS Computational Biology; NIH study section service for panels including Infectious Disease Epidemiology, Statistics, and BMRD; review of CDC and WHO technical reports in an external expert capacity; and service on technical advisory groups evaluating modeling approaches used in national outbreak response. Study section service for NIH is documented through confirmation from the Center for Scientific Review and constitutes selection by an external expert authority that the petitioner has sufficient expertise to evaluate research proposals in the field — a threshold that many active infectious disease modelers with solid research programs do not meet.
Critical role evidence for infectious disease modelers most often attaches to leadership of a modeling consortium or center, direction of an independent research group whose models have been adopted by public health agencies, or primary authorship of analyses that shaped specific public health decisions. A researcher who led the modeling team providing transmission projections for a state's COVID-19 response planning, directed an NIH-funded MIDAS center, or served as the primary technical expert for a WHO outbreak modeling advisory group holds a role whose criticality to an organizational mission can be articulated by declaration from the officials who relied on the work. That reliance relationship — rather than academic titles alone — is the core of the critical role argument for applied researchers.
High salary for infectious disease modelers varies substantially by sector. Academic researchers at R1 institutions are compensated according to their institution's faculty salary scale; AAMC data disaggregated by department and rank provides the relevant comparison for academic positions. Industry-based modelers — at pharmaceutical companies conducting infectious disease epidemiology, at health economics consultancies, or at technology companies with public health data analytics divisions — are compensated according to private sector scales that substantially exceed academic levels. BLS OEWS data for epidemiologists (SOC 19-1041) and statisticians (SOC 15-2041) provides a reference range for public sector and academic positions; private sector compensation surveys provide the relevant industry benchmark.
Building a complete evidence strategy
An effective O-1A petition for an infectious disease modeler leads with publications and original contributions, because those criteria present the most direct evidence of the petitioner's research standing. The publications exhibit should organize papers by impact tier — high-impact general science outlets first, then flagship field journals, then specialized outlets — with each paper's citation count, a brief description of its finding, and where applicable the specific downstream publications, CDC reports, or WHO documents that cited and used the finding. For researchers with COVID-19 pandemic modeling papers, the petition should contextualize those papers carefully to avoid having extraordinary pandemic-era visibility overshadow or substitute for the underlying sustained career record.
Grant documentation should be accompanied by a declaration from a researcher or public health professional familiar with the NIH and CDC grant review processes, explaining what competitive selection at each funding mechanism signifies about the petitioner's standing within infectious disease modeling. Many adjudicators understand intuitively that NIH grants are competitive, but the specific significance of a MIDAS center grant versus an individual R01, or a CDC cooperative agreement versus an NIH supplement, requires expert explanation to carry full persuasive weight. The declaration should explain the review structure, the approximate competitiveness of the pool, and why the petitioner's selection reflects extraordinary achievement rather than ordinary professional success.
Expert declarations for an infectious disease modeler petition are most persuasive when they come from declarants in different institutional sectors — academic researchers, public health agency officials, and clinical infectious disease specialists — who can collectively attest that the petitioner's work is recognized as extraordinary across the field's professional communities. A petitioner whose modeling work is recognized by a senior academic epidemiologist, a CDC program official who implemented the petitioner's approach in agency operations, and a pharmaceutical company medical director who relied on the petitioner's disease burden estimates in clinical trial design presents a multi-sector recognition record establishing standing across the field rather than within a single professional silo. The petition narrative should explain how each declarant's institutional perspective adds distinct probative value.
What we typically gather for this kind of case
| Document | Where to source | Why it matters |
|---|---|---|
| Peer-reviewed publications | Web of Science / Scopus exports | Anchors original-contributions and authorship criteria |
| Citation analysis | Google Scholar profile + ESI top-1% data | Quantifies major significance in the field |
| Salary benchmark | BLS OEWS for SOC code + locality | Documents high-salary criterion at 90th-percentile or above |
| Critical-role letters | Direct supervisor + program director | Establishes role's importance, not just title |
What we see go wrong, again and again
- 01Treating extraordinary ability as a credentials checklist rather than a story of field-wide impact.
- 02Submitting bibliometric data (h-index, citation counts) without explaining what makes those numbers high relative to peers in the same sub-field.
- 03Relying on letters from collaborators or co-authors rather than independent experts who can speak to influence.
See if you qualify
Lando reviews your background against the O-1A visa criteria and tells you honestly where you stand. Free, no commitment.